Urogen's Chief Medical Officer Insider Trade: 400K Sale Insights
A high-profile insider sale at UroGen Pharma raises questions about market signals and biotech risk. This article unp...
Index funds combine broad market exposure with low expenses, often improving risk-adjusted returns for long-term investors. This guide explains the appeal.
22,458 articlesA high-profile insider sale at UroGen Pharma raises questions about market signals and biotech risk. This article unp...
Investors are asking whether the AI infrastructure boom is a bubble. This article dives into real-world data, global ...
Jamie Dimon's latest warning is fueling questions about risk, debt, and AI-driven momentum. This analysis breaks down...
MP Materials is catching investor attention again in 2026 as policy support, domestic production efforts, and a risin...
Amazon ends Walmart’s long hold on the Fortune 500 top spot, posting 2025 revenue of $716.9 billion to Walmart’s $713...
Enterprise Products Partners closed 2025 with record cash flow and a steady ~6% yield, extending a 26-year payout str...
Tension in the Middle East threatens to throttle energy flows, with oil and gas markets reacting as investors reasses...
Stratasys is stepping into 2025 with a focused plan to diversify revenue, improve margins, and scale software-led ser...
As the Iran conflict enters its fourth month, public support remains tepid and markets react differently. This story ...
When a major fund buys more while a stock falls, it sets up a compelling investing puzzle. This piece explains what t...
As Taysha prepares to share Q4 2025 results, investors search for clarity on cash runway, pipeline progress, and futu...
A steep 2026 selloff has investors weighing Microsoft through a new lens. This guide breaks down the case for microso...